|
Sorry, aber merkst du noch was? Unterstellungen, Unterstellungen, Unterstellungen 2 Account - gehts dir noch gut? Ich melde mich hier alle paar Wochen mal zu Wort und dann sind das "permanente Grabreden" ?! LOOOL Ich kann verstehen, dass euch der A... auf Grundeis geht und ihr Frust habt. Aber bitte sachlich bleiben, denn was Ihr von mir verlangt, solltet ihr selbst mal einhalten ... wie war das noch gleich mit dem Spiegel ?! Aber für euch, mal Fakten: Covidien Revascularization Device Approved for Interventional Management of Stroke Trial Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that
the Solitaire™ FR Revascularization Device has been approved for investigational use in the
Interventional Management of Stroke (IMS III) trial. The Solitaire FR device was approved by the
IMS III Executive Committee in the thrombectomy arm of the trial and was included in a recently
approved amendment submitted to the U.S. Food and Drug Administration (FDA). The IMS III Trial will compare a combined intravenous (IV) and intra-arterial (IA) treatment
approach to restoring blood flow to the brain to the current standard FDA-approved treatment
approach of giving IV rTPA alone. A projected 900 subjects with moderate to severe ischemic
stroke will be enrolled at over 50 centers in the United States, Canada, Australia and potentially
Europe. The Executive Committee approved the Solitaire FR device to ensure that the study and
patients have the most advanced treatment technologies to help determine the role of endovascular therapy in acute ischemic stroke. “We are excited to include the Solitaire FR Revascularization Device in the National Institute of
Neurological Disorders and Stroke-funded IMS III trial. The addition of the device will help to
expedite the completion of this critical trial,” said Dr. Joseph Broderick, IMS III Principal
Investigator, Professor and Chair of the Department of Neurology, University of Cincinnati. Outside the United States, the Solitaire FR device has become the leading technology for the
endovascular treatment of acute ischemic stroke, providing stroke physicians with an innovative
treatment technology over the existing options. The high success rate, fast procedure time and
ease of use experienced by physicians in Europe and other regions who have used the device
led physicians to request that it be included in the IMS III Trial. “The Solitaire FR is the first stent-based mechanical thrombectomy device allowed into the
study by IMS III investigators,” said Mark A. Turco, MD, Chief Medical Officer, Vascular
Therapies, Covidien. “We look forward to the important results that will follow from this study
around the optimal treatment of acute ischemic stroke.” ABOUT COVIDIEN Covidien is a leading global healthcare products company that creates innovative medical
solutions for better patient outcomes and delivers value through clinical leadership and
excellence. Covidien manufactures, distributes and services a diverse range of industry-leading
product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With
2011 revenue of $11.6 billion, Covidien has 41,000 employees worldwide in more than 65
countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business. Business Wire
January 30, 2012 - 7:00 AM EST Older reply post Newer threaded view go to top Share Gefällt mir add to favorites COV interesting reading Covidien Revascularization Device Approved for Interventional Management of Stroke Trial Covidien COV | 1/30/2012 7:00: Auf deutsch: Bedeutet, das die Zeit für Desmo abläuft weil wieder ein PIII mit einem neuen Wirkstoff von der Konkurrenz gestartet wird. time is running out ...
|
Thread abonnieren
